{"schema_version":"secwatch.filing_event.v1","accession":"0001539497-24-000541","form_type":"8-K","ticker":null,"cik":"0001358403","company_name":"BELLICUM PHARMACEUTICALS, INC","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.945226+00:00","generated_at":"2026-06-05T21:51:09.285368+00:00","sec_items":["2.01","5.07","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bellicum Pharmaceuticals completes $8.1M asset sale to MD Anderson; stockholder approval of dissolution","bullets":["Sale of CaspaCIDe, iMC, GoCAR-T, and Rimiducid assets to MD Anderson for $8.1M cash.","Stockholders approved both the asset purchase agreement and dissolution plan at reconvened special meeting on Feb 20, 2024.","Super Voting Stock holder cast 11,901,026 votes; total 15,626,551 votes present for quorum.","Asset Sale Proposal passed with 14,372,239 for, 1,243,426 against; Dissolution Proposal passed with 14,317,520 for.","Company now plans to liquidate and dissolve under Delaware law, subject to satisfaction of liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001539497-24-000541","json":"https://secwatch.observer/filing/0001539497-24-000541.json","markdown":"https://secwatch.observer/filing/0001539497-24-000541.md","text":"https://secwatch.observer/filing/0001539497-24-000541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000541/0001539497-24-000541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000541/n3936_x4-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:51:09.285368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2628684f82915d4c88010a3cbc04f3a76274295","claim":"BELLICUM PHARMACEUTICALS, INC completed a disposition involving The University of Texas M. D. Anderson Cancer Center for $8.1 million in cash (closed 2024-02-21).","evidence_excerpt":"2023. Pursuant to the Asset Purchase Agreement, MDACC has acquired the Transferred Assets and assumed certain liabilities for a purchase price in an aggregate amount equal to $8.1 million in cash. The description of the Asset Purchase Agreement contained in this Current Report on Form 8-K is not complete and is qualified in its entirety by reference to the Asset","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000541/0001539497-24-000541-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"The University of Texas M. D. Anderson Cancer Center"},{"label":"Consideration","value":"$8.1 million in cash"},{"label":"Closing","value":"2024-02-21"}],"fact_type":"ma_transaction"},{"claim_id":"30ac981173fd9944bcd34c5188835467057220b7","claim":"BELLICUM PHARMACEUTICALS, INC shareholders approved Approval of the Asset Purchase Agreement and Asset Sale at the 2024-02-20 meeting.","evidence_excerpt":"Proposal 1. Approval of the Asset Purchase Agreement and Asset Sale The Company’s stockholders approved the proposal to adopt and approve the Asset Purchase Agreement, providing for the Asset Sale, which may be deemed under Delaware law to be a sale of substantially all of the Company’s assets, and the consummation of the other transactions contemplated by the Asset Purchase Agreement (the “Asset Sale Proposal” or “Proposal 1”). The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 14,372,239 1,243,426 10,885 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000541/0001539497-24-000541-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-20"}],"fact_type":"shareholder_vote"},{"claim_id":"682d38de827808c3c5b1075c7cf68e57f611cf0a","claim":"BELLICUM PHARMACEUTICALS, INC shareholders approved Approval of the Dissolution Proposal at the 2024-02-20 meeting.","evidence_excerpt":"Proposal 2. Approval of the Dissolution Proposal The Company’s stockholders approved the proposal to approve, subject to approval of Proposal 1, the liquidation and dissolution of the Company in accordance with Section 275 of the Delaware General Corporation Law (the “Dissolution”) and pursuant to a Plan of Dissolution (as defined in the Information Statement) which authorized the Company to liquidate and dissolve in accordance with the Plan of Dissolution (the “Dissolution Proposal” or “Proposal 2”). The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 14,317,520 1,302,337 6,694 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949724000541/0001539497-24-000541-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-02-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}